RxSight Inc.

RXST

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Nov 14, 2025

SC 13G/ARA Capital Management9.9%Nov 14, 2024

SC 13G/A

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 52,257Value: $545K

# Signal Note: Deerfield Initiates RxSight Position Deerfield's $545K entry into RXST signals confidence in the company's light-adjustable lens (LAL) franchise for cataract surgery, which addresses postoperative refractive error without reoperation. The position timing may reflect optimism around LAL adoption metrics, reimbursement expansion, or upcoming commercial catalysts, though the modest position size suggests a reconnaissance stake rather than conviction-level investment.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RDNT1 fund VTR1 fund PHVS1 fund PMVP1 fund ALHC1 fund ATRC1 fund BCRX1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: